Retinopathy of Prematurity (ROP) Clinical Trial
Official title:
Multicenter Randomized Double Masked Parallel Design Exploratory Study to Assess Safety and Efficacy of Two Different Doses of Intravitreal Anti-VEGF Treatment With Ranibizumab (0.12 mg vs. 0.20 mg) in Infants With Retinopathy of Prematurity (ROP)
This study is designed as an exploratory study to assess safety and efficacy of two
different doses of the anti-VEGF agent ranibizumab (0.12 mg vs. 0.20 mg) in the treatment of
infants with retinopathy of prematurity. Furthermore it shall help to improve safety in the
treatment of ROP and provide explorative data on long-term effects of ranibizumab after
intravitreal injection in neonates.
The primary objective is to assess clinical efficacy of ranibizumab in children with ROP
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04506619 -
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
|
||
Completed |
NCT04004208 -
Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy
|
Phase 3 | |
Recruiting |
NCT03253263 -
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
|
Phase 2 | |
Completed |
NCT02386839 -
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
|
Phase 2 | |
Withdrawn |
NCT01470430 -
VEGF In Systemic Circulation Of ROP-infants
|
N/A | |
Completed |
NCT01054027 -
Study on Effective Mydriasis in Premature Infants
|
N/A | |
Active, not recruiting |
NCT04015180 -
Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090
|
Phase 3 | |
Completed |
NCT01096784 -
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
|
Phase 2 | |
Completed |
NCT02640664 -
Rainbow Extension Study
|
Phase 3 | |
Terminated |
NCT01954082 -
Inositol to Reduce Retinopathy of Prematurity
|
Phase 3 |